Atea Pharmaceuticals, Inc. — Director's Dealing 2023

Jun 21, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2023-06-16

Reporting Person: Murphy Polly A. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-16	Restricted Stock Units	$	A	33150	Acquired		Common Stock (33150)	Direct
2023-06-16	Stock Option (Right to Buy)	$4.12	A	46750	Acquired	2033-06-15	Common Stock (46750)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F3: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.